Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Tumor necrosis factor-alpha (TNF-α) is an inflammatory cytokine produced by macrophages in acute inflammatory processes and plays roles in cell signaling that cause necrosis and apoptosis. This study aimed to show whether there was an effect of Neuroaid (MLC 901) on TNF-α levels in rats with traumatic brain injury (TBI) measured using the Enzyme-linked immunosorbent assay in the peripheral blood.
Methods: A total of 10 Sprague-Dawley rats were divided into two groups, one group was given MLC 901 ( = 5), and the other group was not given MLC 901 (NaCl 0.9%) ( = 5). All groups were treated with brain injury using the modified Marmarou model. The measurements of TNF-α were performed at 30 min and 6 weeks after brain injury.
Results: At 30 min after brain injury, the TNF-α level in the MLC 901 group was higher (3564.8) than the 0.9% NaCl group (3453.6), but it was not statistically significant ( = 0.830). At 6 weeks of treatment, the TNF-α level in the MLC 901 group (2576.6) was higher than the 0.9% NaCl group (1383.4) and statistically significant ( = 0.001). This study showed that the administration of MLC 901 could increase TNF-α levels at 6 weeks after treatment.
Conclusion: MLC 901 increases TNF-α levels in rats with TBI, with a significant rise observed at 6 weeks, suggesting a sustained inflammatory response.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255181 | PMC |
| http://dx.doi.org/10.25259/SNI_301_2025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Increased levels of tumor necrosis factor-alpha in rat with traumatic brain injury after NeuroAid (MLC 901) administration.
Surg Neurol Int
June 2025
Department of Neurosurgery, Faculty of Medicine, Diponegoro University, Semarang, Central Java, Indonesia.
Background: Tumor necrosis factor-alpha (TNF-α) is an inflammatory cytokine produced by macrophages in acute inflammatory processes and plays roles in cell signaling that cause necrosis and apoptosis. This study aimed to show whether there was an effect of Neuroaid (MLC 901) on TNF-α levels in rats with traumatic brain injury (TBI) measured using the Enzyme-linked immunosorbent assay in the peripheral blood.
Methods: A total of 10 Sprague-Dawley rats were divided into two groups, one group was given MLC 901 ( = 5), and the other group was not given MLC 901 (NaCl 0.
A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury.
PLoS One
July 2025
National Institute for Stroke and Applied Neurosciences, School of Clinical Sciences, Faculty of Health and Environmental Sciences, Auckland University of Technology, Auckland, New Zealand.
Introduction: About half of the world population will suffer from a traumatic brain injury (TBI) during their lifetime, of which about 90% of cases are mild TBI. Although up to 40% of adults with mild TBI experience persistent functional deficits, there is no proven-effective treatment to facilitate recovery after it.
Methods And Analysis: This randomized placebo-controlled multi-centre study was aimed to examine the efficacy of herbal supplement MLC901 on complex attention following mild TBI at 6 months post-randomisation, as a primary outcome measured by CNS Vital signs (CNS-VS).
Evaluation of Neuroprotective and Neuroregenerative Potential of NeuroAiD™ II(MLC901) in a Rat Model of Kainic Acid-Induced Spinal Cord Injury.
Mol Neurobiol
June 2025
Department of Tissue Engineering and Regenerative Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, 56000, Kuala Lumpur, Cheras, Malaysia.
Excitotoxic damage caused by high extracellular levels of glutamate in the spinal cord results in neuronal loss and severe locomotor impairment. This study investigates the efficacy of NeuroAiD II (MLC901), an herbal formulation, in promoting nerve regeneration following spinal cord injury (SCI) induced by kainic acid (KA). KA, a potent glutamate receptor agonist, causes excitotoxic damage in the spinal cord, leading to neuronal loss and locomotor impairment.
View Article and Find Full Text PDFCost-effectiveness of MLC601 in post-stroke functional recovery compared with placebo - the CHIMES & CHIMES-E studies.
BMC Health Serv Res
September 2024
Raffles Neuroscience Centre, Raffles Hospital, 585 North Bridge Road, #09-00, Singapore, 188770, Singapore.
Background: Despite progress in stroke therapy (e.g., revascularisation interventions by thrombolysis and/or thrombectomy, organised stroke care), many stroke survivors will have impairment of neurological function.
View Article and Find Full Text PDFNeuroAiD-II (MLC901) Promoted Neurogenesis by Activating the PI3K/AKT/GSK-3β Signaling Pathway in Rat Spinal Cord Injury Models.
Biomedicines
August 2024
Department of Tissue Engineering and Regenerative Medicine, Faculty of Medicine, University Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.
Traumatic damage to the spinal cord (SCI) frequently leads to irreversible neurological deficits, which may be related to apoptotic neurodegeneration in nerve tissue. The MLC901 treatment possesses neuroprotective and neuroregenerative activity. This study aimed to explore the regenerative potential of MLC901 and the molecular mechanisms promoting neurogenesis and functional recovery after SCI in rats.
View Article and Find Full Text PDF